Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

E Söreskog, I Lindberg, J A Kanis, K E Åkesson, D Willems, M Lorentzon, O Ström, P Berling, F Borgström, E Söreskog, I Lindberg, J A Kanis, K E Åkesson, D Willems, M Lorentzon, O Ström, P Berling, F Borgström

Abstract

Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture.

Purpose: To estimate the cost-effectiveness of sequential treatment with romosozumab followed by alendronate ("romosozumab-to-alendronate") compared with alendronate alone in patients with severe osteoporosis at high risk of fracture in Sweden.

Methods: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), for women treated with romosozumab-to-alendronate or alendronate alone. Patients aged 74 years with a recent major osteoporotic fracture (MOF) were followed from the start of treatment until the age of 100 years or death. Treatment with romosozumab for 12 months was followed by alendronate for up to 48 months or alendronate alone with a maximum treatment duration of 60 months. The analysis had a societal perspective. Efficacy of romosozumab and alendronate were derived from phase III randomized controlled trials. Resource use and unit costs were collected from the literature. Cost-effectiveness was estimated using incremental cost-effectiveness ratio (ICER) with QALYs as effectiveness measures.

Results: The base case analysis showed that sequential romosozumab-to-alendronate treatment was associated with 0.089 additional QALYs at an additional cost of €3002 compared to alendronate alone, resulting in an ICER of €33,732. At a Swedish reference willingness-to-pay per QALY of €60,000, romosozumab-to-alendronate had a 97.9% probability of being cost-effective against alendronate alone. The results were most sensitive to time horizon, persistence assumptions, patient age, and treatment efficacy.

Conclusion: The results of this study indicate that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture.

Keywords: Cost-effectiveness; Economic evaluation; Imminent fracture risk; Markov-microsimulation model; Osteoporosis; Recent fracture.

Conflict of interest statement

ES, IL, and FB are employees of Quantify Research which was contracted and paid by UCB Pharma to conduct the study. The authors did not receive direct payment as a result of this work outside of their normal salary payments. PB and DW are employees of UCB Pharma. JAK reports grants from Amgen, Eli Lilly, and Radius Health; consulting fees from Theramex. JAK is the architect of FRAX® but has no financial interest. KEA reports lecture and advisory fees outside this work from Amgen, Astellas, Chugai, Renapharma, and UCB Pharma. ML received lecture fees outside this work from Amgen, Astellas, Eli Lilly, UCB Pharma, Radius Health, Meda, GE-Lunar, and Santax Medico/Hologic.

Figures

Fig. 1
Fig. 1
Model structure. ‘Death’ is a transition state from any of the other states (‘At risk of fracture’, ‘Vertebral fracture’, ‘Hip fracture’, and ‘Non-hip, non-vertebral fracture’)
Fig. 2
Fig. 2
Trajectory of fracture risk after first fracture with sequential and non-sequential treatment and without treatment
Fig. 3
Fig. 3
Cost-effectiveness acceptability curves for pairwise comparisons of romosozumab-to-alendronate vs. alendronate alone. Note: WTP levels of €60,000 and €80,000 are indicated by the grey vertical lines

References

    1. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2013;8:136. doi: 10.1007/s11657-013-0136-1.
    1. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137. doi: 10.1007/s11657-013-0137-0.
    1. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, Epidemiology, IOFWGo, and Quality of, L A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–2256. doi: 10.1007/s00198-012-1964-3.
    1. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669–674. doi: 10.1007/s001980070064.
    1. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–382. doi: 10.1016/j.bone.2004.03.024.
    1. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721–739. doi: 10.1359/jbmr.2000.15.4.721.
    1. Banefelt J, Åkesson KE, Spångéus A, Ljunggren O, Karlsson L, Ström O, Ortsäter G, Libanati C, Toth E. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int. 2019;30(3):601–609. doi: 10.1007/s00198-019-04852-8.
    1. Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013;28(11):2317–2324. doi: 10.1002/jbmr.1968.
    1. Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775–780. doi: 10.1007/s00198-016-3868-0.
    1. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99–102. doi: 10.1136/ard.2008.092775.
    1. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, Group, IOFFW Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8):2135–2152. doi: 10.1007/s00198-013-2348-z.
    1. Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507–1529. doi: 10.1007/s00198-016-3894-y.
    1. Jonsson E, Eriksson D, Akesson K, Ljunggren O, Salomonsson S, Borgstrom F, Strom O. Swedish osteoporosis care. Arch Osteoporos. 2015;10:222. doi: 10.1007/s11657-015-0222-7.
    1. European Medicines Agency (2020) Evenity (romosozumab)
    1. EVENITY (romosozumab) Summary of Product Characteristics
    1. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. doi: 10.1056/NEJMoa1708322.
    1. Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12. doi: 10.1007/s00198-019-05176-3.
    1. Swedish Medical Products Agency (Läkemedelsverket) (2020) Pharmaceuticals for osteoporosis to prevent fragility fractures– treatment recommendation ["Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer– behandlingsrekommendation"]
    1. Söreskog, S, Borgström, F, Lindberg, I, Ström, O, Willems, D, Libanati, C, Kanis, JA, Stollenwerk, B, Charokopou, M (2020) A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Manuscript submitted
    1. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22(3):967–982. doi: 10.1007/s00198-010-1424-x.
    1. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Group, FR Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927.
    1. Landfeldt E, Strom O, Robbins S, Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish adherence register analysis (SARA) Osteoporos Int. 2012;23(2):433–443. doi: 10.1007/s00198-011-1549-6.
    1. Jonsson E, Eriksson D, Åkesson K, Ljunggren Ö, Salomonsson S, Borgström F, Ström O. Swedish osteoporosis care. Arch Osteoporos. 2015;10(1):24. doi: 10.1007/s11657-015-0222-7.
    1. Soreskog E, Strom O, Spangeus A, Akesson KE, Borgstrom F, Banefelt J, Toth E, Libanati C, Charokopou M. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50years and older. Bone. 2020;134:115286. doi: 10.1016/j.bone.2020.115286.
    1. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline, G A systematic review of intervention thresholds based on FRAX : a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25. doi: 10.1007/s11657-016-0278-z.
    1. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res. 2012;27(2):243–254. doi: 10.1002/jbmr.1494.
    1. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024–2030. doi: 10.1001/archinte.164.18.2024.
    1. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20(9):1507–1513. doi: 10.1359/JBMR.050501.
    1. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417–427. doi: 10.1007/s001980170112.
    1. Statistics Sweden (2018) Ettårig livslängdstabell, dödsrisker (promille), efter kön, ålder och år
    1. Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjö K, Thorngren KG. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006;17(5):637–650. doi: 10.1007/s00198-005-0015-8.
    1. Davis Sea (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161). Assessment report. Table 32., National Institute for Health and Care Excellence (NICE) (ed)
    1. Nanjayan SK, John J, Swamy G, Mitsiou K, Tambe A, Abuzakuk T. Predictors of change in 'discharge destination' following treatment for fracture neck of femur. Injury. 2014;45(7):1080–1084. doi: 10.1016/j.injury.2014.02.005.
    1. The Dental and Pharmaceutical Benefits Agency (TLV) (2019) Price database Alendronate. 2019-12-10]
    1. The Dental and Pharmaceutical Benefits Agency (TLV) (2017) Ändring i Tandvårds- och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar
    1. Kanis JA, Johansson H, Oden A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgstrom F, McCloskey EV. Characteristics of recurrent fractures. Osteoporos Int. 2018;29(8):1747–1757. doi: 10.1007/s00198-018-4502-0.
    1. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–635. doi: 10.1023/A:1013171831202.
    1. The Dental and Pharmaceutical Benefits Agency (TLV) Kostnadseffektiva läkemedel (Cost-effective pharmaceuticals). 2020-06-23]; Available from:
    1. The Dental and Pharmaceutical Benefits Agency (TLV) (2014) Reimbursement decision Prolia. of Medium] Last Update [cited Access 2014; Available from:
    1. Svensson, M and Nilsson, FJL(2016) TLV: s betalningsvilja för nya läkemedel har analyserats: Kostnadseffektivitet och sjukdomens svårighetsgrad avgörande för subvention-Cancerläkemedel får kosta mer. 113(28–30)
    1. Borgstrom F, Strom O, Marin F, Kutahov A, Ljunggren O. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ. 2010;13(3):381–392. doi: 10.3111/13696998.2010.499072.
    1. Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26(10):2401–2411. doi: 10.1007/s00198-015-3253-4.
    1. Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31(10):1817–1828

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner